临床特征和临床结果的性别差异在CLOROTIC (结合循环与非补偿性心力衰竭的 thiazide 利尿剂) 试验
A Conde-Martel1, J C Trullàs2, J L Morales-Rull3
1Internal Medicine Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain; Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
Revista clinica espanola
|January 12, 2024
概括
将化添加到化中有效治疗急性心力衰竭,对男性和女性都有类似的益处. 然而,女性患功能恶化的发病率更高.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 急性心力衰竭 (AHF) 的管理通常涉及利尿剂.
- 在CLOROTIC试验中显示,化物化物 (HCTZ) 加化物改善了AHF的利尿反应.
- 调查AHF治疗反应中的基于性别的差异至关重要.
研究的目的:
- 分析用HCTZ加上furosemide治疗的AHF患者的性别特异性临床特征和结果.
- 为了评估HCTZ在AHF中添加到furosemide的疗效和安全性,按性别分层.
主要方法:
- 在AHF患者中对CLOROTIC试验 (n=230) 的后期分析.
- 患者接受了静脉注射的罗西米德与HCTZ或安慰剂.
- 主要结局:体重变化和呼吸障碍;次要结局:利尿反应,死亡率和再住院.
主要成果:
- 女性 (48%) 年龄较大,射出分数较高;男性患有较多的缺血性心肌病和较高的性尿素.
- 补充HCTZ改善了体重减轻,利尿反应和24小时利尿在两性同样改善.
- 妇女的功能恶化明显比男性更频繁 (OR 8.68) (OR 2.5).
结论:
- 甲酸与富洛塞米德结合的甲酸是有效的改善尿液反应在AHF,不论性别.
- 虽然这种组合治疗通常是安全的,但对女性来说,功能恶化的风险更高.
- 需要进一步研究性特异性脏对AHF尿剂治疗的反应.
相关概念视频
Conduct Disorder
36
Conduct disorder is a complex mental health diagnosis characterized by a repetitive and persistent pattern of behavior that violates societal norms, the rights of others, or age-appropriate rules. The diagnostic criteria for conduct disorder require the presence of at least three problematic behaviors within the past 12 months, with at least one occurring in the past six months. These behaviors are grouped into four categories: aggression toward people and animals; destruction of property;...
36
Clinical Trials
6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.7K
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
X-linked Traits
54.9K
In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
54.9K
Testing a Claim about Population Proportion
3.3K
A complete procedure for testing a claim about a population proportion is provided here.
There are two methods of testing a claim about a population proportion: (1) Using the sample proportion from the data where a binomial distribution is approximated to the normal distribution and (2) Using the binomial probabilities calculated from the data.
The first method uses normal distribution as an approximation to the binomial distribution. The requirements are as follows: sample size is large...
There are two methods of testing a claim about a population proportion: (1) Using the sample proportion from the data where a binomial distribution is approximated to the normal distribution and (2) Using the binomial probabilities calculated from the data.
The first method uses normal distribution as an approximation to the binomial distribution. The requirements are as follows: sample size is large...
3.3K
Hazard Ratio
128
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
128


